Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Dylan Scott Lykke Harwood"'
Autor:
Dylan Scott Lykke Harwood, Vilde Pedersen, Nicolai Schou Bager, Ane Yde Schmidt, Tobias Overlund Stannius, Aušrinė Areškevičiūtė, Knud Josefsen, Dorte Schou Nørøxe, David Scheie, Hannah Rostalski, Maya Jeje Schuang Lü, Alessio Locallo, Ulrik Lassen, Frederik Otzen Bagger, Joachim Weischenfeldt, Dieter Henrik Heiland, Kristoffer Vitting-Seerup, Signe Regner Michaelsen, Bjarne Winther Kristensen
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-14 (2024)
Abstract Glioblastoma remains one of the deadliest brain malignancies. First-line therapy consists of maximal surgical tumor resection, accompanied by chemotherapy and radiotherapy. Malignant cells escape surgical resection by migrating into the surr
Externí odkaz:
https://doaj.org/article/c9a8d9f57fc34c07b292a1cad2634555
Autor:
Dylan Scott Lykke Harwood, Frantz Rom Poulsen, Torben A Kruse, Christian Bonde Pedersen, Mark Burton, Atul Anand, Bo Halle, Bjarne Winther Kristensen, Mads Thomassen, Rikke Sick Andersen
Publikováno v:
Anand, A, Andersen, R S, Burton, M, Harwood, D S L, Poulsen, F R, Halle, B, Pedersen, C B, Kruse, T A, Thomassen, M & Kristensen, B 2021, ' IMMU-51. Single-cell analysis of tumor-associated microglia and macrophages from human glioblastoma ', Neuro-Oncology, vol. 23, no. Suppl. 6, pp. vi104 . https://doi.org/10.1093/neuonc/noab196.410
Patients with glioblastoma, the most frequent and malignant primary brain tumor type, have a poor prognosis with a median survival of 14 months. A major therapeutic problem is chemoresistance. In surgically removed glioblastoma tissue, tumor-associat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7967bf22ba318d7162dae8b13a40dda2
https://portal.findresearcher.sdu.dk/da/publications/3c499b34-e842-40dd-8fe6-8b228e854de1
https://portal.findresearcher.sdu.dk/da/publications/3c499b34-e842-40dd-8fe6-8b228e854de1
Publikováno v:
Cancers, Vol 13, Iss 4255, p 4255 (2021)
Andersen, R S, Anand, A, Harwood, D S L & Kristensen, B W 2021, ' Tumor-associated microglia and macrophages in the glioblastoma microenvironment and their implications for therapy ', Cancers, vol. 13, no. 17, 4255 . https://doi.org/10.3390/cancers13174255
Cancers
Andersen, R S, Anand, A, Harwood, D S L & Kristensen, B W 2021, ' Tumor-associated microglia and macrophages in the glioblastoma microenvironment and their implications for therapy ', Cancers, vol. 13, no. 17, 4255 . https://doi.org/10.3390/cancers13174255
Cancers
Simple Summary Patients with glioblastoma—the most frequent and malignant primary brain tumor—have a poor prognosis with a median survival of less than 15 months. Despite extensive research, treatment of glioblastoma has not improved since 2005.
Autor:
Mark Burton, Dylan Scott Lykke Harwood, Mads Thomassen, Martin Jakob Larsen, Frantz Rom Poulsen, Jeanette Krogh Petersen, Peter Grupe, Christian Bonde Pedersen, Bjarne Winther Kristensen, Torben A Kruse, Lars van Brakel Andersen, Atul Anand
Publikováno v:
Anand, A, Krogh Petersen, J, Burton, M, Larsen, M J, Andersen, L V B, Harwood, D S L, Pedersen, C B, Poulsen, F R, Grupe, P, Kruse, T A, Thomassen, M & Kristensen, B W 2021, ' OTEH-4. Deeper insight into intratumoral heterogeneity by MRI and PET-guided stereotactic biopsies from glioblastoma patients ', Neuro-Oncology Advances, vol. 3, no. Suppl. 2, pp. ii11 . https://doi.org/10.1093/noajnl/vdab070.043
Neuro-oncology Advances
Neuro-oncology Advances
Glioblastoma is one of the most aggressive cancers, but the molecular evolution is still not fully understood. We used PET imaging combined with deep sequencing of glioblastoma biopsies at both the RNA and DNA levels to get a deeper insight into mole
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1eed72c5b1b7bf8ac8b00b81fa4ba561
https://portal.findresearcher.sdu.dk/da/publications/44c65871-631a-4d3a-a77f-68b8681607fb
https://portal.findresearcher.sdu.dk/da/publications/44c65871-631a-4d3a-a77f-68b8681607fb
Publikováno v:
Neuro-Oncology. 23:vi77-vi78
BACKGROUND The standard therapy for glioblastoma patients is tumor resection followed by radiotherapy and temozolomide chemotherapy. Although glioblastoma has been extensively molecularly profiled along with other cancers, this knowledge has not yet